MGRXMANGOCEUTICALS, INC.

Nasdaq www.mangorx.com


$ 0.27 $ 0.01 (2.78 %)    

Friday, 13-Sep-2024 15:59:43 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 0.27
-- x --
-- x --
-- - --
$ 0.14 - $ 1.19
181,499
na
8.07M
$ -3.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 10-27-2023 09-30-2023 10-Q
5 07-28-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mangorx-receives-certificate-of-grant-in-india-for-its-respiratory-illness-and-preventive-care-technology-patent-application-no-202117034253

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, an...

 mangorx-completes-migration-to-dea-approved-telemedicine-operating-system-accelerating-timeline-of-oral-dissolvable-glp-1-weight-loss-treatments-featuring-semaglutide-and-tirzepatide

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, an...

 mangoceuticals-initiates-efficacy-studies-on-patented-respiratory-illness-prevention-technology-in-collaboration-with-vipragen-biosciences-and-intramont-technologies

Studies Pre-Funded, No Additional Capital Needed; Expected Completion Early Q3 2024

 mangorx-gets-patent-notice-of-allowance-in-japan-for-revolutionary-preventive-care-technology

Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, an...

 mangorx-introduces-mojo-pharmaceutical-compounded-formula-featuring-enclomiphene-citrate-and-pregnenolone-for-treatment-of-low-testosterone-and-male-hormone-imbalances--sold-exclusively-on-mangorxs-website-on-a-subscription-basis-at-a-price-of-199-per-month

MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testoste...

 mangoceuticals-develops-oral-glp-1s-stock-soars

Mangoceuticals announced the development of proprietary oral formulations of Semaglutide ("Slim") and Tirzepatide ("...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION